Alpha Cognition's ZUNVEYL, FDA-approved in July 2024, targets Alzheimer's with improved tolerability over existing galantamine therapies. ZUNVEYL's pricing is competitive versus newer Alzheimer's ...

Corcept Therapeutics has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing Corcept prescriptions due to its ...